Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that …
val of a product or impose restrictions on its distribution, such as in the form of a REMS. The failure to obtain timely regulatory approval of product candidates, any product marketing limitations o…
Reciprocal relationship from SNYNF graph: Reciprocal relationship from FDMT graph: val of a product or impose restrictions on its distribution, such as in the form of a REMS. The failure to obtain ti…
Reciprocal relationship from RGNX graph: Reciprocal relationship from FDMT graph: Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2…
val of a product or impose restrictions on its distribution, such as in the form of a REMS. The failure to obtain timely regulatory approval of product candidates, any product marketing limitations o…
Reciprocal relationship from SNYNF graph: Reciprocal relationship from FDMT graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from FDMT graph: Reciprocal relationship from SNYN…
4D Molecular Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
FDMT-DEBT
Debt stack $20.5M
90%
Market cache reports total debt of $20.5M.
FDMT-DEBT-9461
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2020-12-31.
FDMT-DEBT-9460
Warrants outstanding: 45000
90%
xbrl warrant detail from xbrl 2025-12-31.
4D Molecular Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for 4D Molecular Therapeutics, Inc..
4D Molecular Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
FDMT-OWNER-JANUS-HENDERSON-GROUP-PLC
JANUS HENDERSON GROUP PLC
90%
13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 152 tracked holders.
4D Molecular Therapeutics, Inc. Extended Supply Chain Network